IRIDEX (NASDAQ:IRIX) Earns Hold Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of IRIDEX (NASDAQ:IRIX) in a report published on Tuesday. The brokerage issued a hold rating on the medical equipment provider’s stock.

IRIDEX Stock Performance

NASDAQ IRIX opened at $0.88 on Tuesday. The company has a debt-to-equity ratio of 0.55, a current ratio of 1.54 and a quick ratio of 0.85. IRIDEX has a 1-year low of $0.78 and a 1-year high of $3.65. The firm has a market capitalization of $14.69 million, a P/E ratio of -1.32 and a beta of 0.94. The business’s 50-day simple moving average is $1.38 and its 200-day simple moving average is $1.59.

IRIDEX (NASDAQ:IRIX) last issued its earnings results on Thursday, March 27th. The medical equipment provider reported ($0.05) EPS for the quarter, meeting analysts’ consensus estimates of ($0.05). The business had revenue of $12.70 million for the quarter, compared to the consensus estimate of $12.80 million. IRIDEX had a negative net margin of 22.79% and a negative return on equity of 192.95%.

IRIDEX Company Profile

IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments.